Market Overview

UPDATE: Morgan Stanley Reiterates On St. Jude Medical On Mixed Factors

Share:
Related STJ
Benzinga's Top Upgrades
Credit Suisse Upgrades St. Jude Medical To Outperform
St. Jude Medical (STJ) Looks Good: Stock Gains 6.4% - Tale of the Tape (Zacks)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on St. Jude Medical (NYSE: STJ), but removed the $75.00 price target.

In the report, Morgan Stanley noted, “We remain comfortable that St. Jude's top line is poised for acceleration given underlying business strength, CRT-D momentum and CardioMEMs. However, Nanostim's early European failures and MDT's more positive comparative experience did raise concerns at HRS.”

St. Jude Medical closed on Thursday at $63.22.

Latest Ratings for STJ

DateFirmActionFromTo
Apr 2015Credit SuisseUpgradesNeutralOutperform
Apr 2015BarclaysMaintainsOverweight
Apr 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (STJ)

Around the Web, We're Loving...